• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. FDA approves Arcalyst technology transfer?
FDA approves Arcalyst technology transfer?

FDA approves Arcalyst technology transfer?

3.5% (24u)Health & MedicineOne-Off7d
PolymarketPolymarketBeschikbaarheid controlerenGeen KYC2% kosten
Huidige impliciete kans
Ja
Ja 81%-0.0%
Marktkwaliteit

49 / 100

Lage kwaliteit
24u volume

€ 0

Liquiditeit

€ 1,5K

Lage liquiditeit
Bied / Laat

80.0% / 82.0%

Spread

2.5%

Strakke spread
Marktdata

Bijgewerkt 2 minuten geleden

4 jun 26, 19:3519 jun 26, 0:00

Trends

Uitkomst24uKans

Gekozen uitkomst

Yes81%

Regels

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Kiniksa & Regeneron's Arcalyst related to the technology transfer to Samsung Biologics as a replacement CDMO by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Gerelateerde Markten

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 145,3K
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 16,6K
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

€ 8,7K
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

€ 1,3K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

€ 462,5
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

€ 137,8
2025: 0%Manifold MarketsMANIFOLD MARKETS

Actief in deze onderwerpen

BitcoinBTC$62,928.32+2.44%EthereumETH$1,659.49+1.68%SolanaSOL$65.34+1.62%DogecoinDOGE$0.085+1.53%XRPXRP$1.12+0.39%BNBBNB$596.89+1.78%

Gerelateerd Nieuws

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regels

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Kiniksa & Regeneron's Arcalyst related to the technology transfer to Samsung Biologics as a replacement CDMO by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs